The Economic Burden of Antibiotic Resistance
Antibiotic resistance not only threatens health but also imposes a heavy economic burden globally. Resistant infections lead to longer treatments, increased hospital stays, and more expensive alternative drugs. Productivity losses due to illness and premature death further amplify costs.
Studies estimate that if unchecked, antibiotic resistance could cost the global economy trillions of dollars by 2050. Low- and middle-income countries are disproportionately affected due to limited healthcare infrastructure and high infectious disease burdens.
The Antibiotic Resistance Market reflects growing investments aimed at mitigating this economic impact through new drug development, diagnostics, and preventive measures.
3 Views